Benzinga | Oct 21, 2021 12:11PM EDT

William Blair Initiates Coverage On Tempest Therapeutics with Outperform Rating

William Blair analyst Matt Phipps initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Outperform rating.